Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three intravenous drugs—propofol, dexmedetomidine, and fentanyl—used for procedural sedation and anesthesia. - **Propofol** is a short-acting hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, producing sedation and hypnosis[2]. - **Dexmedetomidine** is a highly selective alpha-2 adrenergic receptor agonist that provides sedative, anxiolytic, and analgesic effects with minimal respiratory depression. It also has sympatholytic properties. - **Fentanyl** is a potent synthetic opioid analgesic that primarily acts as an agonist at the mu-opioid receptor to provide strong analgesia[1]. The combination leverages synergistic effects for deep sedation or general anesthesia while aiming to minimize individual drug doses and their respective side effects. This regimen may be used in various settings such as surgery or intensive care procedures where rapid onset and titratable depth of anesthesia are required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + dexmedetomidine + fentanyl.